Apellis Pharmaceuticals, Inc.

This program offers early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and active kidney damage. Participants must have a confirmed diagnosis and limited response to other trea…

This study looks at the safety and how doctors use Syfovre (pegcetacoplan) in routine care for 300 people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. Participants receive the drug as prescribed by their doctor, and researc…

This study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…

This study looks at the long-term safety and effectiveness of pegcetacoplan in people with PNH, a rare blood disorder. Participants must have completed a prior pegcetacoplan study and shown benefit. The main goal is to track side effects over time.